Last reviewed · How we verify
whole blood collection
Whole blood collection is a phlebotomy procedure that obtains blood from a donor for transfusion, diagnostic testing, or therapeutic purposes.
Whole blood collection is a phlebotomy procedure that obtains blood from a donor for transfusion, diagnostic testing, or therapeutic purposes. Used for Blood transfusion for anemia or blood loss, Diagnostic laboratory testing, Therapeutic phlebotomy.
At a glance
| Generic name | whole blood collection |
|---|---|
| Sponsor | CHU de Reims |
| Modality | Biologic |
| Therapeutic area | Hematology/Transfusion Medicine |
| Phase | FDA-approved |
Mechanism of action
Whole blood collection involves venipuncture to extract blood containing red blood cells, white blood cells, platelets, and plasma. The collected blood can be used directly for transfusion, separated into components for specific therapeutic needs, or processed for diagnostic laboratory analysis. This is a foundational clinical procedure rather than a pharmacological drug.
Approved indications
- Blood transfusion for anemia or blood loss
- Diagnostic laboratory testing
- Therapeutic phlebotomy
- Blood component separation and processing
Common side effects
- Vasovagal syncope
- Hematoma at venipuncture site
- Dizziness or lightheadedness
- Nausea
Key clinical trials
- Collection of Blood From Patients With Prostate Cancer
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- whole blood collection CI brief — competitive landscape report
- whole blood collection updates RSS · CI watch RSS
- CHU de Reims portfolio CI